Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 163

1.

[Classification of myeloid leukemias].

Kuriyama K.

Nihon Rinsho. 2009 Oct;67(10):1853-62. Review. Japanese.

PMID:
19860179
2.

Myeloproliferative neoplasms: contemporary diagnosis using histology and genetics.

Tefferi A, Skoda R, Vardiman JW.

Nat Rev Clin Oncol. 2009 Nov;6(11):627-37. doi: 10.1038/nrclinonc.2009.149. Epub 2009 Oct 6. Review.

PMID:
19806146
3.

The World Health Organization (WHO) classification of tumors of the hematopoietic and lymphoid tissues: an overview with emphasis on the myeloid neoplasms.

Vardiman JW.

Chem Biol Interact. 2010 Mar 19;184(1-2):16-20. doi: 10.1016/j.cbi.2009.10.009. Epub 2009 Oct 24. Review.

PMID:
19857474
4.

The 2008 World Health Organization classification system for myeloproliferative neoplasms: order out of chaos.

Tefferi A, Thiele J, Vardiman JW.

Cancer. 2009 Sep 1;115(17):3842-7. doi: 10.1002/cncr.24440.

5.

Hematologic malignancies with PCM1-JAK2 gene fusion share characteristics with myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB, and FGFR1.

Patterer V, Schnittger S, Kern W, Haferlach T, Haferlach C.

Ann Hematol. 2013 Jun;92(6):759-69. doi: 10.1007/s00277-013-1695-3. Epub 2013 Feb 12.

PMID:
23400675
6.

Recent advances in the diagnosis and classification of myeloid neoplasms--comments on the 2008 WHO classification.

Yin CC, Medeiros LJ, Bueso-Ramos CE.

Int J Lab Hematol. 2010 Oct;32(5):461-76. doi: 10.1111/j.1751-553X.2010.01246.x. Epub 2010 Jul 7. Review.

7.

Myelodysplastic syndrome with inv(3)(q21q26.2) or t(3;3)(q21;q26.2) has a high risk for progression to acute myeloid leukemia.

Cui W, Sun J, Cotta CV, Medeiros LJ, Lin P.

Am J Clin Pathol. 2011 Aug;136(2):282-8. doi: 10.1309/AJCP48AJDCKTHUXC.

8.
9.

Classification and diagnosis of myeloproliferative neoplasms according to the 2008 World Health Organization criteria.

Wadleigh M, Tefferi A.

Int J Hematol. 2010 Mar;91(2):174-9. doi: 10.1007/s12185-010-0529-5. Epub 2010 Feb 27. Review.

PMID:
20191332
10.

World health organization classification, evaluation, and genetics of the myeloproliferative neoplasm variants.

Vardiman J, Hyjek E.

Hematology Am Soc Hematol Educ Program. 2011;2011:250-6. doi: 10.1182/asheducation-2011.1.250. Review.

PMID:
22160042
11.

Classification of myeloid neoplasms: a comparative review.

McManus PM.

Vet Clin Pathol. 2005 Sep;34(3):189-212. Review.

PMID:
16134066
12.

JAK2 V617F mutation in myelodysplastic syndrome, myelodysplastic syndrome/myeloproliferative neoplasm, unclassifiable, refractory anemia with ring sideroblasts with thrombocytosis, and acute myeloid leukemia.

Jekarl DW, Han SB, Kim M, Lim J, Oh EJ, Kim Y, Kim HJ, Min WS, Han K.

Korean J Hematol. 2010 Mar;45(1):46-50. doi: 10.5045/kjh.2010.45.1.46. Epub 2010 Mar 31.

13.
14.

New classification of acute myeloid leukemia and precursor-related neoplasms: changes and unsolved issues.

Falini B, Tiacci E, Martelli MP, Ascani S, Pileri SA.

Discov Med. 2010 Oct;10(53):281-92. Review.

15.

Treatment of progression of Philadelphia-negative myeloproliferative neoplasms to myelodysplastic syndrome or acute myeloid leukemia by azacitidine: a report on 54 cases on the behalf of the Groupe Francophone des Myelodysplasies (GFM).

Thepot S, Itzykson R, Seegers V, Raffoux E, Quesnel B, Chait Y, Sorin L, Dreyfus F, Cluzeau T, Delaunay J, Sanhes L, Eclache V, Dartigeas C, Turlure P, Harel S, Salanoubat C, Kiladjian JJ, Fenaux P, Ad├Ęs L; Groupe Francophone des Myelodysplasies (GFM).

Blood. 2010 Nov 11;116(19):3735-42. doi: 10.1182/blood-2010-03-274811. Epub 2010 Jul 27.

16.

Classification of chronic myeloid disorders: from Dameshek towards a semi-molecular system.

Tefferi A, Gilliland G.

Best Pract Res Clin Haematol. 2006;19(3):365-85. Review.

PMID:
16781478
17.

Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders.

Cortes J, Giles F, O'Brien S, Thomas D, Albitar M, Rios MB, Talpaz M, Garcia-Manero G, Faderl S, Letvak L, Salvado A, Kantarjian H.

Cancer. 2003 Jun 1;97(11):2760-6.

18.

Diagnosing myelodysplastic/myeloproliferative neoplasms: laboratory testing strategies to exclude other disorders.

Hall J, Foucar K.

Int J Lab Hematol. 2010 Dec;32(6 Pt 2):559-71. doi: 10.1111/j.1751-553X.2010.01251.x. Review.

PMID:
20670271
19.

Myelodysplastic/myeloproliferative neoplasms.

Hyjek E, Vardiman JW.

Semin Diagn Pathol. 2011 Nov;28(4):283-97. Review.

PMID:
22195406
20.

Characterization of NPM1-mutated AML with a history of myelodysplastic syndromes or myeloproliferative neoplasms.

Schnittger S, Bacher U, Haferlach C, Alpermann T, Dicker F, Sundermann J, Kern W, Haferlach T.

Leukemia. 2011 Apr;25(4):615-21. doi: 10.1038/leu.2010.299. Epub 2011 Jan 14.

PMID:
21233837
Items per page

Supplemental Content

Write to the Help Desk